Core Viewpoint - Longevity Health Holdings, Inc. has received approval from the Nasdaq Hearings Panel to continue its listing on Nasdaq, contingent upon meeting initial listing rules following its proposed merger with 20/20 BioLabs by September 2, 2025 [1][3]. Company Overview - Longevity Health Holdings focuses on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [1][4]. - The company offers two regenerative technologies: Carmell Secretome™ and Elevai Exosomes™, aimed at improving skin and hair health [4]. Merger Details - The proposed merger with 20/20 BioLabs includes a strategic plan to effect a 1-for-30 reverse stock split to meet Nasdaq's listing requirements [2]. - The S-4 registration statement for the merger was filed on May 8, 2025, and the reverse stock split was executed on May 12, 2025 [2]. 20/20 BioLabs Overview - 20/20 BioLabs specializes in developing innovative laboratory tests for early detection and management of chronic disease risks, including a multi-cancer early detection blood test available in the U.S. [5]. - The company plans to introduce a new blood test for monitoring chronic inflammation, which is linked to several leading causes of death in America [5].

PITTSBURGH and GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on extending human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition (“XAGE”, the “Company”, “we”, “our”, or “us”), today announced the following business updates: 1. Merger Agreement entered with 20/20 BioLabs (“20/20”) Merger Agreement executed on April 11, 2025, pursuant t ...

PITTSBURGH, May 12, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (NASDAQ: XAGE) (“Longevity” or the “Company”), a bio-aesthetics company focused on longevity and healthy aging, today announced that it has resolved to effect a reverse stock split of the Company’s common stock and has determined the ratio to be 1-for-30. The Company’s stockholders approved the reverse stock split and granted the Longevity board of directors the authority to determine the exact split ratio and when to proceed with ...

PITTSBURGH, Pa. & GAITHERSBURG, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition (“Longevity”, the “Company”, “we”, “our”, or “us”), today announced the execution of a merger agreement (the “Merger”) with 20/20 BioLabs, Inc. (“20/20”), a leading provider of innovative laboratory tests for the ...